|
**Overview**: PML RARA t(15;17) PCR Panel**Introduction**: The PML RARA t(15;17) PCR Panel is a diagnostic tool designed to detect PML-RARA rearrangement using whole blood or bone marrow samples. In India, acute promyelocytic leukemia (APL) accounts for ~10-15 percent of acute myeloid leukemias (~5,000-7,000 cases/year), with t(15;17) present in nearly all cases, conferring excellent prognosis with ATRA + arsenic trioxide. High morbidity from under-testing in rural/low-SES patients with pancytopenia or DIC, limited molecular labs, delayed ATRA initiation leading to fatal hemorrhage or differentiation syndrome. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs PCR for PML-RARA t(15;17), fusion transcript, and qualitative result over 1-2 days with high sensitivity, valuable for rapid APL confirmation and MRD monitoring. This diagnostic falls under leukemia screening and targets patients with suspected APL (promyelocytes, DIC), addressing accurate detection to guide urgent ATRA/ATO therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling prompt APL management and improving cure rates. Its blood/bone marrow-based approach ensures reliable fusion detection.**Other Names**: PML RARA PCR Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/hematology/oncology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: PML-RARA PCR standard in APL since 1990s; in India, routine in leukemia centers.**Purpose**: The test assesses 3 parameters including PML-RARA t(15;17) to guide APL screening, confirm fusion, inform ATRA/ATO therapy.**Test Parameters**: 1. PML-RARA t(15;17), 2. Fusion Transcript, 3. Qualitative Result.**Pretest Condition**: No fasting required; patients should have suspected APL.**Specimen**: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on bleeding, pancytopenia.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected APL including hemorrhage, benefits of confirmation, and minimal discomfort from sampling.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low blast count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive PML-RARA confirms APL, necessitating urgent specialist input.**Specialist Consultation**: Hematologists/oncologists should be consulted for management.**Additional Supporting Tests**: Flow cytometry, karyotype for confirmation.**Test Limitations**: Detects fusion only; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Leukemia Studies India 2023. |
